Coming Tomorrow Morning Does a weight-loss plateau mean your GLP-1 receptors have become desensitized? John separates cellular receptor biology from whole-body weight regulation and compares semaglutide, tirzepatide, and investigational retatrutide. We examine appetite suppression, food noise, gastric-emptying tachyphylaxis, metabolic adaptation, switching therapies, and what the clinical evidence can—and cannot—tell us. A plateau is real. “Receptor burnout” is a much bigger claim. Educational only; not medical advice.

So, being new to this…silly me bought 10mls Reta to reconstitute with 3mls BAC. My dose is 0.25 weekly. I now have 40 doses reconstituted if my calculations are correct…please correct me if I’m wrong 🙏 meaning that if it only lasts 30 days in the fridge, I have far too much and will have to dispose of it. Argh! Please help.

Eli Lilly Just Sued Six Companies for Selling Retatrutide. Here Is What It Means for Access Going Forward Eli Lilly filed six federal lawsuits on August 12, 2026, against vendors selling retatrutide, and the choice of legal theory tells you almost everything you need to understand about what is actually happening here. Before getting into any of the specific legal mechanisms, here is the full picture: Lilly holds a patent on retatrutide that covers the molecule under any name, they are simultaneously fighting a separate case to get the compound classified in a legal category that would permanently block compounding pharmacies from ever making it, every current vendor is exposed to enforcement from multiple directions at once, and the lawsuits filed so far represent a fraction of the enforcement action already in motion. That is the map. Now here is what each piece of it means. The lawsuits are filed under false advertising law and against the distribution of an unapproved drug, not under patent law, and that distinction is worth sitting with for a moment. Patent infringement is the more obvious tool here, given that Lilly holds US Patent 11,542,313 B2 on this molecule since January 2023, covering the compound itself, the manufacturing processes, specific formulations, and methods of treatment. That patent does not expire until approximately January 2039, with continuation patents that can push coverage further. Lilly could have led with patent claims. They chose not to. The reason is optics and sequencing. When a pharmaceutical company sues for patent infringement, the narrative that emerges is a corporation protecting its revenue. When the same company sues for false advertising and distribution of an unapproved drug, the narrative is a corporation protecting consumers from unsafe, unverified products. Lilly's legal team made a deliberate choice to enter this fight framed as a safety issue rather than a commercial one, and that framing matters for how regulators, courts, and the public receive the cases.

Got notified this morning that my channel has been deleted by YouTube. Onward and upward my friends. I’m Rethinking things and figuring out next steps. This will not change anything here or on the podcast platforms. The reality is that the topic of peptides is a very controversial subject and more is coming for the majority of content creators very soon. My goal is and has always been to provide the data in a clear concise package. I will continue to do just that moving forward regardless of restrictions, suspensions or cancellations. Stay tuned

I need 2 volunteers to check out something with me. (peptide related of course…not an actual peptide, but in relation to them) Any takers?